These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 21763469

  • 1. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C, Borghgraef P, Matarazzo V, Gielis L, Lajard AM, Voituron N, Gestreau C, Dutschmann M, Van Leuven F, Hilaire G.
    Respir Physiol Neurobiol; 2011 Sep 15; 178(2):290-303. PubMed ID: 21763469
    [Abstract] [Full Text] [Related]

  • 2. Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei.
    Dutschmann M, Menuet C, Stettner GM, Gestreau C, Borghgraef P, Devijver H, Gielis L, Hilaire G, Van Leuven F.
    J Neurosci; 2010 Feb 03; 30(5):1810-21. PubMed ID: 20130190
    [Abstract] [Full Text] [Related]

  • 3. Isoflurane anesthesia precipitates tauopathy and upper airways dysfunction in pre-symptomatic Tau.P301L mice: possible implication for neurodegenerative diseases.
    Menuet C, Borghgraef P, Voituron N, Gestreau C, Gielis L, Devijver H, Dutschmann M, Van Leuven F, Hilaire G.
    Neurobiol Dis; 2012 Apr 03; 46(1):234-43. PubMed ID: 22316605
    [Abstract] [Full Text] [Related]

  • 4. Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders.
    Menuet C, Cazals Y, Gestreau C, Borghgraef P, Gielis L, Dutschmann M, Van Leuven F, Hilaire G.
    PLoS One; 2011 Apr 03; 6(10):e25770. PubMed ID: 22022446
    [Abstract] [Full Text] [Related]

  • 5. Terminal hypothermic Tau.P301L mice have increased Tau phosphorylation independently of glycogen synthase kinase 3α/β.
    Maurin H, Lechat B, Borghgraef P, Devijver H, Jaworski T, Van Leuven F.
    Eur J Neurosci; 2014 Jul 03; 40(2):2442-53. PubMed ID: 24754737
    [Abstract] [Full Text] [Related]

  • 6. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.
    Exp Neurol; 2008 Jul 03; 212(1):71-84. PubMed ID: 18490011
    [Abstract] [Full Text] [Related]

  • 7. Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy.
    Crespo-Biel N, Theunis C, Borghgraef P, Lechat B, Devijver H, Maurin H, Van Leuven F.
    Neurobiol Dis; 2014 Jul 03; 67():119-32. PubMed ID: 24704314
    [Abstract] [Full Text] [Related]

  • 8. Tauopathy in the periaqueductal gray, kölliker-fuse nucleus and nucleus retroambiguus is not predicted by ultrasonic vocalization in tau-P301L mice.
    Trevizan-Baú P, Dhingra RR, Burrows EL, Dutschmann M, Stanić D.
    Behav Brain Res; 2019 Sep 02; 369():111916. PubMed ID: 31004684
    [Abstract] [Full Text] [Related]

  • 9. T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice.
    Fukushima T, Nakamura A, Iwakami N, Nakada Y, Hattori H, Hoki S, Yamaguchi H, Nakagawa M, Terashima N, Narita H.
    Biochem Biophys Res Commun; 2011 Apr 22; 407(4):730-4. PubMed ID: 21439944
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
    Köhler C, Bista P, Götz J, Schröder H.
    Brain Res; 2010 Aug 06; 1347():111-24. PubMed ID: 20513372
    [Abstract] [Full Text] [Related]

  • 11. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
    Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F.
    J Biol Chem; 2005 Feb 04; 280(5):3963-73. PubMed ID: 15509565
    [Abstract] [Full Text] [Related]

  • 12. Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease.
    Dengler-Crish CM, Smith MA, Wilson GN.
    J Alzheimers Dis; 2017 Feb 04; 55(4):1605-1619. PubMed ID: 27814296
    [Abstract] [Full Text] [Related]

  • 13. Interneuronal transfer of human tau between Lamprey central neurons in situ.
    Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF.
    J Alzheimers Dis; 2010 Feb 04; 19(2):647-64. PubMed ID: 20110609
    [Abstract] [Full Text] [Related]

  • 14. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
    Kulic L, Wollmer MA, Rhein V, Pagani L, Kuehnle K, Cattepoel S, Tracy J, Eckert A, Nitsch RM.
    Neurobiol Aging; 2011 Oct 04; 32(10):1827-38. PubMed ID: 19942317
    [Abstract] [Full Text] [Related]

  • 15. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model.
    Ando K, Leroy K, Heraud C, Kabova A, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP.
    Biochem Soc Trans; 2010 Aug 04; 38(4):1001-5. PubMed ID: 20658993
    [Abstract] [Full Text] [Related]

  • 16. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
    David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Götz J.
    Proteomics; 2006 Dec 04; 6(24):6566-77. PubMed ID: 17111439
    [Abstract] [Full Text] [Related]

  • 17. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M.
    Eur J Neurosci; 2008 Jul 04; 28(2):239-46. PubMed ID: 18702695
    [Abstract] [Full Text] [Related]

  • 18. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
    Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N.
    Brain Res; 2016 Mar 01; 1634():158-170. PubMed ID: 26746341
    [Abstract] [Full Text] [Related]

  • 19. Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy.
    Maurin H, Chong SA, Kraev I, Davies H, Kremer A, Seymour CM, Lechat B, Jaworski T, Borghgraef P, Devijver H, Callewaert G, Stewart MG, Van Leuven F.
    PLoS One; 2014 Mar 01; 9(2):e87605. PubMed ID: 24498342
    [Abstract] [Full Text] [Related]

  • 20. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
    Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH.
    Brain Res Mol Brain Res; 2005 Aug 18; 138(2):135-44. PubMed ID: 15913839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.